Will UiPath's (PATH) Move Into AI Security Shape Its Long-Term Competitive Edge?

  • Earlier this month, the Artificial Intelligence Underwriting Company (AIUC) announced that UiPath has become a founding technical contributor to AIUC-1, a leading enterprise security framework for AI agent adoption rooted in global standards and third-party audits.
  • UiPath’s involvement underscores its commitment to strengthening AI security and compliance for organizations using autonomous agent technologies in critical workflows.
  • Now, let's explore how UiPath’s new leadership role in AI enterprise security could influence its investment narrative going forward.

AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Advertisement

UiPath Investment Narrative Recap

To be a UiPath shareholder, it's important to believe in the company's ability to capitalize on enterprise automation and AI security, backed by deep partnerships and robust compliance standards. The recent announcement of UiPath’s role as a founding technical contributor to the AIUC-1 enterprise security framework signals commitment to trusted AI adoption, yet is unlikely to materially shift the immediate revenue impact of delayed enterprise deals or challenges posed by macroeconomic uncertainty in the short term.

Of UiPath’s recent announcements, the multi-faceted collaboration with NVIDIA stands out in relation to the AIUC-1 news. Both focus on advancing secure and efficient AI-led automation in business-critical areas, whether through joint technical frameworks or applied AI in sensitive sectors, highlighting how UiPath is positioning its platform as a key enabler for secure, compliant workflow automation as adoption of autonomous agents accelerates.

But in contrast, investors should be aware of how ongoing geopolitical delays in enterprise deal closures have ...

Read the full narrative on UiPath (it's free!)

UiPath's outlook anticipates $1.9 billion in revenue and $243.6 million in earnings by 2028. This projection assumes an 8.6% annual revenue growth rate and a $311.1 million increase in earnings from the current level of -$67.5 million.

Uncover how UiPath's forecasts yield a $13.86 fair value, in line with its current price.

Exploring Other Perspectives

PATH Community Fair Values as at Nov 2025
PATH Community Fair Values as at Nov 2025

The Simply Wall St Community shared 13 fair value estimates for UiPath ranging from US$13.70 to US$30.00, showing broad differences in outlook. Your view on the company’s ability to overcome delayed enterprise deal closures could be a key factor shaping performance in the months ahead, explore the many perspectives and decide what matters most to you.

Explore 13 other fair value estimates on UiPath - why the stock might be worth over 2x more than the current price!

Build Your Own UiPath Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

Ready For A Different Approach?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NYSE:PATH

UiPath

Provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally.

Flawless balance sheet and undervalued.

Advertisement

Weekly Picks

ST
stuart_roberts
UG logo
stuart_roberts on Upside Gold ·

An Undervalued 3.3Moz Gold Project in Canada

Fair Value:CA$5.0775.1% undervalued
64 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative
JA
KO logo
Jades on Coca-Cola ·

Coca-Cola’s Enduring Moat in a Health-Conscious World: Steady Compounder Poised for 5-10% Annual Returns Through Emerging Market Dominance

Fair Value:US$66.221.2% overvalued
19 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
ET
XRO logo
Ethan_cpa on Xero ·

Xero: Growth Was Priced In — Execution Is Not

Fair Value:AU$101.5622.4% undervalued
10 users have followed this narrative
1 users have commented on this narrative
6 users have liked this narrative
KA
NU logo
kabz2342 on Nu Holdings ·

Nu holdings will continue to disrupt the South American banking market

Fair Value:US$64.376.4% undervalued
47 users have followed this narrative
3 users have commented on this narrative
27 users have liked this narrative

Updated Narratives

VA
TLX logo
Vallix on Telix Pharmaceuticals ·

TLX... a Market's Overreaction or a Falling Knife?

Fair Value:AU$1845.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KA
SGM logo
kabstck on Sims ·

Rally in sustainable practices over value recyclable metal stock

Fair Value:AU$18.0717.7% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
VE
Vestra
REGN logo
Vestra on Regeneron Pharmaceuticals ·

Regeneron Pharmaceuticals Inc. (REGN): The Biotech Stalwart – Defensive Growth Amid Biosimilar Headwinds in 2026.

Fair Value:US$893.8811.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.888.0% undervalued
65 users have followed this narrative
5 users have commented on this narrative
28 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$59633.1% undervalued
1300 users have followed this narrative
2 users have commented on this narrative
10 users have liked this narrative
KA
NU logo
kabz2342 on Nu Holdings ·

Nu holdings will continue to disrupt the South American banking market

Fair Value:US$64.376.4% undervalued
47 users have followed this narrative
3 users have commented on this narrative
27 users have liked this narrative